从活用四逆汤看“扶阳”学术思想的继承与发展

四逆汤源自《伤寒论》,是治疗少阴阳虚阴寒证的代表方,病机主要为阳虚,但阳虚病机同中有异,故其所治病症的主证既可为手足逆冷,又可为下利清谷、呕吐等其他表现,不拘于四肢逆冷一症。郑钦安深得仲景"扶阳"学术思想宗旨,对阳虚病情辨认细致入微,灵活运用四逆汤治疗多种病症。吴佩衡在继承《伤寒论》及郑钦安扶阳学术思想的基础上,细究四逆汤各药物的功效以及配伍特点,强调早用四逆诸方,扶阳固本,将四逆汤的临床应用范围扩大至六经病之阴寒证以及内、妇、儿、外科等多种阳虚阴寒危重病症的治疗。     

Hypothermic Machine Perfusion's Protection on Porcine Kidney Graft Uncovers Greater Akt-Erk Phosphorylation

Background

To investigate the potential mechanisms of hypothermic machine perfusion (HMP)'s beneficial effects on kidney graft over static cold storage (SCS) in vitro.

郑启仲运用升降散规律研究

目的:研究郑启仲教授运用升降散用药规律。方法:通过收集郑启仲教授门诊处方,录入中医传承辅助平台,使用软件的统计报表模块、数据分析模块和关联规则apriori算法等数据挖掘方法,分析处方中药物应用频次、药物组合频次等,并进行关联规则分析,重点分析发热和咳嗽为主症的用药规律,研究郑启仲教授运用升降散用药规律。结果:应用关联规则分析发现升降散常与柴胡、黄芩、生石膏、甘草等配伍。发热为主症的疾病常用处方:升降散、普济消毒饮、银翘散等,多与生石膏、栀子、浙贝母、羚羊角等药物配伍。咳嗽为主症的疾病常用处方:升降散、麻杏石甘汤、三拗汤、小柴胡汤等,多与川贝母、莱菔子、连翘、栀子、葶苈子、羚羊角等配伍。结论:郑启仲教授灵活运用升降散治疗儿科外感温病及内伤杂病,擅用升清降浊治法,组方用药体现了升清降浊的治疗思想。     

“痁,病也”考

"病"字的本义是"困苦",词性为动词或形容词。"病"的本义非"重病",甚至也不是"病重"。众多引申义中有"疾危重"一义,在"疾危重"基础上进一步引申出带有形容词性质的"疾危重的状态"义,进而才引申出名词性质的"疾病"义、"病者"义。这正可以解释许多不同义项的字都可以用"某,病也"来训诂的语言现象,而且清晰反映出"病"的本义困苦在身体、精神、国家方面的各引申义,以及本义引申义在实际语言活动中丰富多变的灵活运用。     

穴贴扶正升白膏对化疗小鼠造血及免疫系统的实验研究

运用扶正升白膏对化疗小鼠进行穴位涂敷的实验研究 ,结果显示 :在化疗的同时 ,使用该膏后 ,可起防止白细胞下降太快或减少过多的作用。其机制是以保护骨髓造血细胞 ,减轻骨髓有核细胞损失为基础 ,故可减轻化疗对免疫系统的伤害     

正露丸微生物限度检查法验证

目的：建立正露丸微生物限度检查法.方法：采用培养基稀释法.结果：能有效消除本品在检验条件下本品对细菌、霉菌及酵母菌、控制菌的抑制作用.结论：该方法简单快捷、准确可行,可用于本品的微生物限度检查,有效控制本品的质量.     

中药内服联合外用治疗干眼症临床研究

目的：观察采用中药内服联合外用治疗干眼症的临床疗效。方法：采用内服杞菊地黄汤、联合外用杞菊地黄汤超声雾化对干眼症患者进行治疗,观察治疗组37例和对照组40例的治疗疗效。结果：治疗组有效率为91.89%,对照组有效率为52.5%。结论：内服杞菊地黄汤联合外用杞菊地黄汤超声雾化治疗干眼症疗效显著。     

郑守谦气功养生经验述要

气功是中医养生学的主要组成部分之一,它在强身祛病,修身养性方面发挥着积极作用。简述了气功的源流与发展及中医气功的基础理论、方法,并详细介绍了已故的著名中医妇科专家郑守谦先生独有心得的气功功法,包括练体、练意、练气的气功要旨以及郑老平素长期坚持练习的内功静坐养生功法,为今人学习、实践气功功法提供了借鉴。     

Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non–Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors

BackgroundThere is an urgent need to develop a convenient and less invasive technique to monitor the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non–small-cell lung cancer (NSCLC). We proposed folate receptor–based assay to count circulating tumor cells (CTCs) to predict and dynamically monitor the therapeutic response to first-line EGFR-TKIs in patients with EGFR-mutated NSCLC.Patients and MethodsEligible patients were enrolled, and 3 mL of blood was obtained before initial treatment, 1 month after treatment, and every 2 months thereafter. CTCs were isolated on the basis of negative enrichment by immunomagnetic beads and detected by a ligand-targeted PCR method.ResultsA total of 232 patients with EGFR-mutated NSCLC and treated with first-line EGFR-TKIs were included. Patients with low baseline CTC count had a markedly longer progression-free survival (hazard ratio = 0.48; P < .001) and overall survival (hazard ratio = 0.52; P = .002) than those with high count. This difference remained significant in multivariate analysis. Dynamic change of CTC count was significantly associated with partial response (P = .042) and stable disease/progressive disease (P = .032). Notably, dynamic monitoring of CTC provided evidence of resistance to EGFR-TKIs before computed tomographic scanning with a median lead time of 113 days (range, 45-169 days).ConclusionThe current evidence suggests that folate receptor–positive CTC counts can be used for both the dynamic monitoring and prediction of outcome in EGFR-mutated NSCLC patients treated with EGFR-TKIs, which could serve as an alternative or supplement to computed tomographic scanning.     

《伤寒论》“主证”辨识

《伤寒论》是一部以讨论外感病为主而阐发运用辨证论治方法的著作,书中仲景既示人以规矩,又诲人以技巧。其言精奥,其法简详,其中第101条:"伤寒中风,有柴胡证,但见一证便是,不必悉具。"后世医家或伤寒论注家对此"一证"争论不休、莫衷一是,对此笔者认为此"一证"定是"主证",其义有二:一为某方所治之证侯;二即某证侯中之主要症状。